🔓 New #CellPreview by Prof. Kai W. Wucherpfennig @harvard.edu highlights our work on LAG3!
Key take:
• Cbl-mediated, non-degradative poly-ubiquitination at K498 unlocks LAG3 signaling
• Marks TILs that respond to PD-1/LAG3 combo
#LAG3 #Immunotherapy #PD1 #TCell
www.cell.com/cell/fulltex...
Key take:
• Cbl-mediated, non-degradative poly-ubiquitination at K498 unlocks LAG3 signaling
• Marks TILs that respond to PD-1/LAG3 combo
#LAG3 #Immunotherapy #PD1 #TCell
www.cell.com/cell/fulltex...
Unlocking LAG3: Ubiquitin’s unexpected role
The inhibitory receptor LAG3 is the target of the FDA-approved mAb relatlimab, but
its mechanism of signaling is not well understood. In this issue of Cell, Jiang et al.
demonstrate that ubiquitinatio...
www.cell.com
May 2, 2025 at 2:08 AM
🔓 New #CellPreview by Prof. Kai W. Wucherpfennig @harvard.edu highlights our work on LAG3!
Key take:
• Cbl-mediated, non-degradative poly-ubiquitination at K498 unlocks LAG3 signaling
• Marks TILs that respond to PD-1/LAG3 combo
#LAG3 #Immunotherapy #PD1 #TCell
www.cell.com/cell/fulltex...
Key take:
• Cbl-mediated, non-degradative poly-ubiquitination at K498 unlocks LAG3 signaling
• Marks TILs that respond to PD-1/LAG3 combo
#LAG3 #Immunotherapy #PD1 #TCell
www.cell.com/cell/fulltex...